{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE303nnn/GSE303798/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303798"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of cetuximab-induced gene expression changes in residual PDX tumors of head and neck squamous cell carcinoma","description":"Cetuximab, a monoclonal antibody targeting EGFR, offers only modest and often transient clinical responses in recurrent or metastatic HNSCC, owing to the persistence of a therapy-tolerant cell population that seeds residual disease and eventual therapeutic failure. Clinical evidence across cancer types indicates that depth of response to targeted therapy correlates with prolonged progression-free survival, highlighting the importance of residual disease as a driver of resistance. However, the molecular features enabling HNSCC cells to tolerate EGFR blockade before the acquisition of stable resistance remain incompletely understood. We analyzed residual tumors from cetuximab-treated patient-derived xenograft (PDX) models of HNSCC (#UCLHN04 and #HNC004) to identify gene expression changes associated with anti-EGFR tolerance in HNSCC cells.","dates":{"publication":"2026/06/22"},"accession":"GSE303798","cross_references":{"GSM":["GSM9136162","GSM9136161","GSM9136153","GSM9136163","GSM9136152","GSM9136155","GSM9136154","GSM9136157","GSM9136156","GSM9136159","GSM9136158","GSM9136160"],"GPL":["24676"],"GSE":["303798"],"taxon":["Homo sapiens"]}}